2. Academic Validation
  3. The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis

The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis

  • Mutat Res Genet Toxicol Environ Mutagen. 2021 Jan-Feb;861-862:503278. doi: 10.1016/j.mrgentox.2020.503278.
Sabry M Attia 1,  Sheikh F Ahmad 2,  Ahmed Nadeem 2,  Mohamed S M Attia 2,  Mushtaq A Ansari 2,  Gamaleldin I Harisa 3,  Mohammed A Al-Hamamah 2,  Mohamed A Mahmoud 2,  Saleh A Bakheet 2
Affiliations

Affiliations

  • 1 Department of Pharmacology and Toxicology, Saudi Arabia. Electronic address: attiasm@ksu.edu.sa.
  • 2 Department of Pharmacology and Toxicology, Saudi Arabia.
  • 3 Kayyali Chair for Pharmaceutical Industry, Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
PMID: 33551096 DOI: 10.1016/j.mrgentox.2020.503278
Abstract

Multiple sclerosis (MS), a disease in which the immune system attacks nerve cells, has been associated with both genetic and environmental risk factors. We observed increased micronucleus (MN) formation in SJL/J mouse experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Most of these MN were due to chromosomal loss. Increased activation of MAP kinases, which leads to disruption of the mitotic spindle and improper segregation of chromosomes, is associated with MS. MAP kinase inhibitors, such as PD98059, may therefore be beneficial for MS. In the EAE model, PD98059 treatment reduced adverse effects, including MN formation, lipid peroxidation, and GSH oxidation. Interventions that mitigate chromosomal instability may have therapeutic value in MS.

Keywords

Aneugenicity; Clastogenicity; Experimental autoimmune encephalomyelitis; Fluorescence in situ hybridization; Oxidative stress.

Figures
Products